Companies › Adagene
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ADG126 anti-CTLA-4 monoclonal antibody | CTLA4 | Phase 1 | Advanced/Metastatic Solid Tumors; Locally Advanced Colorectal Cancer | Jun 2027 |
| ADG206 activatable anti-CD137 monoclonal antibody (IgG1 co-stimulatory agonist) | CD137 | Phase 1 | Advanced/Metastatic Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05614258 | ADG206 | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | Jun 2025 |
| NCT05405595 | ADG126 | Phase 1 | Advanced/Metastatic Solid Tumors | Oncology | Jun 2027 |
| NCT06846268 | ADG126 | Phase 2 | Locally Advanced Colorectal Cancer | Oncology | Dec 2027 |
Cash and short-term investments of $75m on 2025-12-31; operating cash outflow about $16m a year; runway about 57 months at that burn, to Sep 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.